Table 1.

Survival time and tumor growth of mice injected with Lovo or CT26 cells inoculated at their spleens

Strain of miceCell injectedTreatmentDays of survivalMedian survival time (d)% of mice with liver metastasis% of mice with spleen tumor
BALB/cLovoAAV-EGFP21, 30, 33, 33, 34, 37334/6 (66.7%)6/6 (100%)
AAV-HGFK133, 34, 36, 37, 43, 5036.54/6 (66.7%)6/6 (100%)
AAV-EGFP+Ad-p5331, 35, 36, 43, 46, 5139.53/6 (50%)6/6 (100%)
AAV-HGFK1+Ad-p5339, 48, 53, 68, 90+, 90+60.52/6 (33.3%)4/6 (66.7%)
Nude miceCT26AAV-EGFP20, 20, 21, 22, 22, 2521.56/6 (100%)6/6 (100%)
AAV-HGFK122, 24, 25, 29, 30, 51276/6 (100%)6/6 (100%)
AAV-EGFP+Ad-p5324, 25, 26, 29, 31, 4727.56/6 (100%)6/6 (100%)
AAV-HGFK1+Ad-p5325, 59, 63, 63, 68, 90+635/6 (83.3%)5/6 (100%)